AbbVie Snapping Up Pharmacyclics For $21 Billion

0
AbbVie Snapping Up Pharmacyclics For $21 Billion
Source: Made with Photoshop

According to Bloomberg sources, AbbVie topped Johnson & Johnson with a last-minute bid to finalize the $21 billion acquisition of Pharmacyclics. to give the firm control of likely best-in-class blood cancer therapy Imbruvica.

Chicago-based AbbVie has agreed to pay $261.25 a share in a mix of cash and stock. According to the sources, Pharmacyclics was nearing an agreement to be acquired by J&J, which was offering about $250 a share, before AbbVie came up with a higher bid.

Robinhood 2021 Conference: Cathie Wood discusses her investment process with Lee Ainslie [Exclusive]

Yarra Square Investing Greenhaven Road CapitalARK Invest is known for targeting high-growth technology companies, with one of its most recent additions being DraftKings. In an interview with Maverick's Lee Ainslie at the Robinhood Investors Conference this week, Cathie Wood of ARK Invest discussed the firm's process and updated its views on some positions, including Tesla. Q1 2021 hedge fund letters, Read More


Statement from AbbVie CEO

AbbVie CEO Richard Gonzalez noted in a statement that “Imbruvica is not only complementary to AbbVie’s oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies.”

More on Pharmacyclics

Pharmacyclics had a net income last year of more than $86 million, based on Bloomberg data. According to an average of analyst estimates, sales of Imbruvica are expected to increase rapidly to $3.56 billion in 2018 from just $492 million last year.

The company has guided for U.S. sales of Imbruvica to surpass $1 billion in 2015, and by 2020 global sales of the cancer drug are anticipated to top $5.8 billion, based on consensus estimates from Thomson Reuters Cortellis.

AbbVie management noted that the deal would be “highly accretive” to both  its revenue and earnings by 2017.

California-based Pharmacyclics co-markets Imbruvica with pharma giant Johnson & Johnson. As well as Imbruvica, the firm has three drug candidates in clinical trials.

Perspective from analyst

Imbruvica will  compete with one of AbbVie’s top pipeline products, cancer drug ABT-199, but there should be market share for both compounds, notes Asthika Goonewardene from Bloomberg Intelligence. ABT-199 may not be approved for more than a year, and while Imbruvica is becoming the gold standard, some patients may benefit from a different therapy. “Given all this, having two dogs in the race may not be a bad thing,” Goonewardene explained in an e-mail interview.

No posts to display